BRUSSELS, BELGIUM--(Marketwire - December 03, 2007) - UCB today announced results of a Phase III trial demonstrating that its antiepileptic drug (AED) in development Keppra XR™ (levetiracetam) extended-release tablets significantly reduced partial onset seizure frequency when administered as adjunctive therapy for adults with refractory epilepsy. These data were presented today at a scientific exhibit at the 61st annual meeting of the American Epilepsy Society, Philadelphia.
